Member Info for Phantom25

It's still not competition in the hospital setting. The Datar system is a screening device it may be an alternative to mamograms or other first contact screening systems. Parsortix is a CTC retrieval device intended to aid down stream treatment decisions, by providing cancer cells for whatever assy the treatment team wish to apply.

I don't see the Datar system as a direct competitor to Parsortix. First it is being marketed as a screening device Parsortix isn't. Next Parsortix enables complete isolated retrieval of virgin(unprocessed) CTCs, there is no mention of this with the Datar. All the microfluidic comparisons that they refer to appear to be cellsearch(R) an old expensive cumbersome system that requires magnetic doped antibodies, again not a virgin CTC

I meant to post this link
https://www.nsmedicaldevices.com/news/cancer-research-study-uses-angles-parsortix-system/

A few lines into the introduction they seem to dismiss any other system including microfluidic devices to isolate CTC clusters. When in fact Parsortix was instrumental in capturing and realising the negative effect on metastatic spread due to clusters.https://angleplc.com/angle-ctc-lab-services/enumeration-of-epithelial-and-mesenchymal-ctc-populations-including-ctc-clusters/

He has no intention of getting on board, his tuktuk is in the car park

No one knows what is around the corner it could be a week it could be a year. As I say it's your call, but it's a risk/reward situation. By waiting the reward is probably 10p saving, the risk could quite easily be a loss £1 or more

By waiting for 40p you potentially miss out on a large rise from significant RNS. Your call but I wouldn't take the risk

Scot's link works for me

It's because you bought at bang in the middle of the quotes. MMs don't report a trade as buy or sell, just a trade. LSE tries to guess

Bantam
I am perfectly happy with the route the company is taking
FL stated that unfortunately there are many steps for Angle to complete. I'm curious to know what these steps are
And to be honest I'm not that bothered with your opinion, someone who has no faith in the company or the board and not invested

FL

You say that it's unfortunate that Angle has a lot of steps to complete. Could you list them?

Don't just suggest that Angle has to expand its IP to include cancer types other than breast cancer, as we've already established that IP already exists

Parsortix is not limited to breast cancer. So to suggest that Angle need to broaden their IP to other cancer types is a tad unfair. I think to date it has been used successfully on 23 cancers,
https://angleplc.com/library/publications/

I never said there was an enormous bid around the corner did I?

Abbott probably know a low ball offer would be rejected AN will not let this go cheap. That only leaves a hostile take over, of which the majority fail, especially if the target company has near term growth potential

FL
You are aware that Parsortix captures and allows retrieval of whole cancer cells not fragments of cells or ctDNA, so with that being said I can't se how it could be used to enhance the blood sample for a PCR based DNA amplification system. Unless I'm missing something.

Just realised who you are, so if that is the start of a deramp campaign - truly pathetic

That's the par value, all AGL shares have a par value of 10p. It's virtually meaningless forget about it

Just to add to Badgers post a blood test requires no specialised real estate, can take a blood test in an office

Well well now my original post has appeared.

One area I've often thought could be be a nice income is vetenary services. Everyone one I know with an aging dog has a problem with tumors. I'm not suggesting AGL get involved with selling or distribution. Find a licensee, Mr supervet for example. Give him an excluse license, let him do the donkey work. There are 29000 vets in the UK. If each vet used the service once per week, that would be £15m per anum for cassettes alone. Also realise that a dog develope a tumor from 7/8 years 8/9 X higher frequency than humans. I would guess regulation would be zero. A nice steady income so no more funding